3 ms·

Do you have an opinion on https://www.science.org/content/blog-post/new-mode-cancer-treatment https://www.science.org/content/blog-post/new-mode-cancer-tr...?

by btilly 3y ago

jseliger 3y ago
Nope. Nothing other than "I hope it works!" Interestingly, AOH1996 is supposed to be given at Honor Health Research Institute: https://beta.clinicaltrials.gov/study/NCT05227326 https://beta.clinicaltrials.gov/study/NCT05227326, which is down the street from me, but the trial isn't listed as recruiting yet. Not sure why: if I weren't in the trial I'm in (https://news.ycombinator.com/item?id=37924671 https://news.ycombinator.com/item?id=37924671), AOH1996 would likely be on the list. It's a first-in-human trial with only 8 participants, and most drugs, even super promising-seeming ones, don't make it even to phase 2. But https://www.clinicaltrials.gov/study/NCT04787042 https://www.clinicaltrials.gov/study/NCT04787042 is also a promising phase 1 trial for an interleukin-18 attack, and it's also at Honor Health.
ramraj07 3y ago
Not who you asked but that’s a promising molecule. Unfortunately until we see phase 1/2 results we can’t be sure if it ends up actually being effective. It’s sad that we can’t predict efficacy any better without injecting actual people with the drug but that’s reality. Cancer is too complex to model any other way in a complete fashion. If a drug is blockbuster effective you’d notice in phase 1 itself, as was the case for ibrutinib. Fingers crossed.
adamredwoods 3y ago
In my air-chair opinion, the future of cancer treatments will not be one "cure-all" drug, but many, all depending on a cancer's characteristics and an individual's response to treatments. Cancer can also mutate or become metastatic when under duress, so the characteristics change then as well. So the more treatments we can create, the better.
- ethbr1 3y ago
  That's been the last 15 years of oncology, afaik. Old: type cancer on location and characteristics, give treatment statistically effective against that combination New: sequence cancer, feed into software, study treatment options and plan from that It's been a huge change.

Do you have an opinion on https://www.science.org/content/blog-post/new-mode-cancer-treatment https://www.science.org/content/blog-post/new-mode-cancer-tr...?

by btilly 3y ago

Do you have an opinion on https://www.science.org/content/blog-post/new-mode-cancer-treatment https://www.science.org/content/blog-post/new-mode-cancer-tr...?

jseliger 3y ago

Nope. Nothing other than "I hope it works!" Interestingly, AOH1996 is supposed to be given at Honor Health Research Institute: https://beta.clinicaltrials.gov/study/NCT05227326 https://beta.clinicaltrials.gov/study/NCT05227326, which is down the street from me, but the trial isn't listed as recruiting yet. Not sure why: if I weren't in the trial I'm in (https://news.ycombinator.com/item?id=37924671 https://news.ycombinator.com/item?id=37924671), AOH1996 would likely be on the list. It's a first-in-human trial with only 8 participants, and most drugs, even super promising-seeming ones, don't make it even to phase 2. But https://www.clinicaltrials.gov/study/NCT04787042 https://www.clinicaltrials.gov/study/NCT04787042 is also a promising phase 1 trial for an interleukin-18 attack, and it's also at Honor Health.

ramraj07 3y ago

Not who you asked but that’s a promising molecule. Unfortunately until we see phase 1/2 results we can’t be sure if it ends up actually being effective. It’s sad that we can’t predict efficacy any better without injecting actual people with the drug but that’s reality. Cancer is too complex to model any other way in a complete fashion. If a drug is blockbuster effective you’d notice in phase 1 itself, as was the case for ibrutinib. Fingers crossed.

adamredwoods 3y ago

In my air-chair opinion, the future of cancer treatments will not be one "cure-all" drug, but many, all depending on a cancer's characteristics and an individual's response to treatments. Cancer can also mutate or become metastatic when under duress, so the characteristics change then as well. So the more treatments we can create, the better.

ethbr1 3y ago
That's been the last 15 years of oncology, afaik. Old: type cancer on location and characteristics, give treatment statistically effective against that combination New: sequence cancer, feed into software, study treatment options and plan from that It's been a huge change.